Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
IPO Year:
Exchange: NYSE
Website: teleflex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2025 | $235.00 → $140.00 | Neutral → Underperform | BofA Securities |
| 2/28/2025 | $220.00 → $155.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/28/2025 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2025 | $255.00 → $140.00 | Overweight → Neutral | Piper Sandler |
| 2/27/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2023 | $261.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/21/2023 | Buy → Hold | Needham | |
| 5/30/2023 | $293.00 | Buy | CL King |
| 5/30/2023 | $261.00 | Equal-Weight | Morgan Stanley |
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.70.5% reduction in the incidence of CLABSI in patien
Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment. WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading globa
Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a global leader in medical technologies, today announced the presentation of compelling new clinical data at the 2025 American Urological Association (AUA) Annua
Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS™ Stapler with reduced rates of post-operative GERD following robotic-assisted laparoscopic sleeve gastrectomy (LSG) compared
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi
WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $700.7 million, down 5.0% compared to the prior year period; down 3.8% on an adjusted constant currency basis GAAP diluted EPS from continuing operations of $2.07, compared to $0.33 in the prior year period Adjusted diluted EPS from continuing operations of $2.91, compared to $3.21 in the prior year period 2025 guidance summary Raising GAAP revenue growth guidance range to 1.28% to 2.28% Maintaining adjusted constant currency revenue growth guidan
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE:TFX), will be presenting at the BofA Securities 2025 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Wednesday, May 14, 2025, at 1:40 p.m. (PT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia
WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical wounds, mild and moderate bleeding in cardiac surgical procedures, and bone surfaces following sternotomy. "Bleeding remains a major contributor to mortality and morbidity in the United S
WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during radiation treatment for prostate cancer. "Understanding how leading treatment options perform—both in rigorous clinical trials and in everyday practice—is essential to empowering the futu
WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all ot